Prevalence of Oncogenic HPV Types in Sardinia (Italy): Implications for the Impact of Prophylactic Anti-HPV Vaccines
Stefania Montisci, Sabrina Pitzalis, Marianna Greco, Alberto Orani, Marco Rais and Sergio Laconi
DOI : 10.3844/ajidsp.2007.134.141
American Journal of Infectious Diseases
Volume 3, Issue 3
Infection with high-risk HPV genotypes is considered an essential step in cervical carcinogenesis. Recently, prophylactic anti-HPV vaccines have shown to provide effective protection in clinical trials. However, protection appears to be type-restricted, thus, its real extent will depend on HPV types prevalence in the target population. Here we report HPV prevalence in 555 Italian women with various stages of HPV-related cervical disease (343 CIN1/L-SIL, 156 CIN2-3/HIGH-SIL, 43 invasive squamous cervical carcinoma and 13 adenocarcinoma), as well as in 315 women with smears negative for intraepithelial lesions or malignancy (NIL). HPV was found in 50.7% of CIN1/L-SIL, 87.2% of CIN2-3/HIGH-SIL, 97.7% of squamous carcinomas, 69.2% of adenocarcinomas and in 29.5% of NIL. HPV 16 was present in 69.0% of squamous carcinomas, 58.8% of CIN2-3/HIGH-SIL, in 22.9 and 16.1% of CIN1/L-SIL and NIL, respectively. HPV 18 was found in 7.3% and 4.8%, respectively, while in 35.3% and 26.2% of CIN2-3/HIGH-SIL and invasive carcinomas, respectively, were present high-risk HPV types other than type 16 and 18. Based on these data, it is expected that current HPV prophylactic vaccines could effectively prevent up to 70% of invasive cervical cancers and a slightly smaller proportion of high-grade lesions, in our population.
© 2007 Stefania Montisci, Sabrina Pitzalis, Marianna Greco, Alberto Orani, Marco Rais and Sergio Laconi. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.